Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 70/100

Failure Rate

60.0%

3 terminated/withdrawn out of 5 trials

Success Rate

40.0%

-46.5% vs industry average

Late-Stage Pipeline

20%

1 trials in Phase 3/4

Results Transparency

150%

3 of 2 completed trials have results

Key Signals

3 with results

Enrollment Performance

Analytics

N/A

1(50.0%)

Phase 3

1(50.0%)

2Total

N/A(1)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials

NCT03302494Phase 3Terminated

WAveCrest Vs. Watchman TranssEptal LAA Closure to REduce AF-Mediated STroke 2

Role: lead

NCT03204695Not ApplicableTerminated

WAVECREST Post Market Clinical Follow-Up (PMCF) Study

Role: lead

NCT01280578Terminated

The Coherex FlatStent™ EF PFO Migraine Registry

Role: lead

NCT02239887Completed

Coherex WAVECREST I Left Atrial Appendage Occlusion Study

Role: lead

NCT01257880Completed

Comorbidities Associated With Migraine and Patent Foramen Ovale (CAMP)

Role: collaborator

All 5 trials loaded